
R^{12} is hydrogen, optionally substituted alkyl, haloalkyl, hydroxy, halo, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, or optionally substituted heteroalkyl;

each R^{13} is independently H, optionally substituted alkyl, haloalkyl, optionally substituted carbocyclyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; and

n is 0, 1, 2, 3, or 4.


[0004a] In one aspect, the present disclosure refers to a compound that is



or a pharmaceutically acceptable salt or solvate thereof.

[0004b] In one aspect, the present disclosure refers to a pharmaceutical composition comprising the compound as described herein and at least one pharmaceutically acceptable excipient.



[0004c] In one aspect, the present disclosure refers to use of a compound that is



or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating prostate cancer, breast cancer, ovarian cancer, or non-small cell lung cancer in a subject in need thereof; wherein the prostate cancer, breast cancer, ovarian cancer, or non-small cell lung cancer expresses glucocorticoid receptor (GR).

CLAIMS

WHAT IS CLAIMED IS:

1. A compound that is  or a pharmaceutically acceptable salt or solvate thereof.
2. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable excipient.
3. Use of a compound that is  or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating prostate cancer, breast cancer, ovarian cancer, or non-small cell lung cancer in a subject in need thereof; wherein the prostate cancer, breast cancer, ovarian cancer, or non-small cell lung cancer expresses glucocorticoid receptor (GR).
4. The use of claim 3, wherein the cancer is chemo-resistant.
5. The use of claim 3, wherein the cancer is breast cancer.
6. The use of claim 5, wherein the cancer is chemo-resistant.
7. The use of claim 3, wherein the cancer is ovarian cancer.
8. The use of claim 7, wherein the cancer is chemo-resistant.
9. The use of claim 3, wherein the cancer is prostate cancer.
10. The use of claim 9, wherein the cancer is chemo-resistant.
11. The use of claim 9, wherein the cancer is castration resistant prostate cancer.
12. The use of any one of claims 3-11, wherein a therapeutically effective amount of a second therapeutic agent is to be further administered to the subject selected from an androgen receptor inhibitor, cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, camptothecin, topotecan, an anti-PD-L1 agent or an anti-PD1 agent, and any combinations thereof.
13. The use of claim 3, wherein the cancer is non-small cell lung cancer.